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I
n 1995, when I left a faculty position at the University of
Pennsylvania to join the ﬂedgling bioinformatics unit at
what was then SmithKline Beecham Pharmaceuticals, the
friendly jibes by academic colleagues about ‘‘going over to the
Dark Side’’ were, I suspect, only half in jest. There weren’t all
that many of us practicing bioinformatics at that time, and
there was genuine concern that a brain drain to industry
might curtail the training of a new generation. Dire talk of
‘‘eating our seed corn’’ made its way into print [1–3].
Other misgivings grew out of the ﬁrst wave of human
genome-wide data then arriving in profusion: the short
single-pass cDNA sequences called expressed sequence tags
(ESTs) that bubbled up new gene identiﬁcations seemingly on
a daily basis and that appeared to be suddenly short-
circuiting the stately, hierarchical progression of the genome
effort through ever-ﬁner stages of mapping while
breakthroughs in sequencing technology were labored after
[4–6]. The data-management challenges arising from this
heady sampling of the genome were making a strong
impression, in both the public and private sectors, and the as-
yet-unresolved (and highly charged) question of the
patentability of genes led to a land rush on intellectual
property [7–9]. At the same time a surge of startups with
liberal venture-capital grubstakes only increased the demand
for skilled gene prospectors [10,11]. All these developments
fed concerns that a reckless commercialization of the human
genome would be somehow unfairly turbocharged by lavish
spending and pure computational horsepower in industry,
with legions of apostate academics mining the data.
Ten Years before the Bench
I had my own concerns in moving to industry, especially as
this was my second such excursion. Once before I had
departed academia, but for another Dark Side: the computer
industry and a job in a central R&D (research and
development) function devoted to artiﬁcial intelligence (AI). I
had joined Burroughs Corporation at the height of the mid-
1980s AI frenzy brought on by advances in computer science
as well as in hardware speed and capacity, advances that had
seemed to leave us on the verge of true ‘‘thinking machines.’’
My reasons then for abandoning the lab and a conventional
biology career path had partly to do with the lure of AI at that
golden moment when all things seemed possible, and partly
with a frustration with what I saw as the slow pace and labor-
intensive nature of biological research. Having spent ten
years before the bench, and suffering from a bad case of
Pipetter’s Thumb, I was ready for a computer to do a little of
the work. Especially appealing was that rather than having to
grow up new bugs from scratch after failed experiments, I
could instead just debug and recompile. To me, computers
were wonderful effort ampliﬁers.
Arriving at Burroughs in 1985 did engender some culture
shock, but I found the pace at which decisions were made and
put into effect bracing after the glacier-paced turnaround
times of the public funding apparatus. Of course, the savings
in time and futility of grantsmanship were roughly offset by
expenditure of time and futility in meetings and corporate
bureaucracy. Also, while the decisions could come with
breathtaking speed, they could still go either way, and what
was more sinister, could arrive unbidden and unanticipated.
At times one longed for the lengthy time constants and highly
structured expectations of academia, though on the whole I
still favored velocity over inertia.
That was during the high summer of AI, which saw not only
a boom in research but also in commercialization, with both
hardware and software startups galore. The president of the
American Association for Artiﬁcial Intelligence (AAAI)
exulted that ‘‘it is clear . . . that our ﬁeld, perhaps together
with molecular genetics, will be society’s predominant
scientiﬁc endeavor for the rest of this century and well into
the next. . . .’’ [12]. With the general buzz around AI, and good
support for pushing the envelope from a computer company
with deep pockets, what I did in industry seemed qualitatively
akin to what I had done in academia. Applied research was
intertwined with basic research, with the latest advances
being brought to bear on ‘‘real-world’’ problems in what
seemed a most felicitous combination [13,14]. It was the AI
startups, rather, that seemed relentlessly product-focused and
technologically conservative, for the sake of making their
next payroll. (It should be noted, though, that one of the more
adventurous such companies at the time was IntelliCorp,
which had recently changed its name from IntelliGenetics—
one of the ﬁrst serious bioinformatics companies and brieﬂy
the home of GenBank [15].)
A Disturbance in the Force
Perhaps such synergy of scientiﬁc advance with commercial
application was too good to last. Several inauspicious trends
converged as the 1980s drew to a close. First, the mainframe
computer business model was rapidly obsolescing, spurring
Burroughs to merge with Sperry to form Unisys—thereby
breeding what many viewed as just a larger dinosaur. The
parent companies had a proud history of advancing
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remembered are just a few vestigial factoids: that Larry Wall
hacked together the Perl scripting language—fundamental to
the development of the Web and bioinformatics—while
holding down a day job at Unisys [16], and that the LZW data
compression algorithm was invented by a research group
there [17]. The patent for LZW, a basic computing
methodology used in several popular graphics formats, made
Unisys a be ˆte noire to Open Source free spirits for years and
inﬂamed the debate about whether it should be possible to
patent something as ‘‘natural’’ as an algorithm [18].
This was my ﬁrst experience with the unnerving corporate
phenomenon of the mega-merger. In the ﬁeld of AI,
Burroughs had stressed R&D while Sperry had focused on
commercialization, which meant that I rather abruptly went
from thinking about knowledge representation and logic
programming to following sales of LISP machines and
turnkey expert system shells (in both cases, products acquired
from startups, including IntelliCorp, and relabelled). To
further complicate matters, at the same time that the
computer industry was having to realign itself, and its
appetite for basic research was diminishing for similar
reasons, the so-called AI Winter set in. Seemingly overnight
the ﬁeld was perceived as an overhyped disappointment and
thus receded from the clamorous marketplace and the glare
of the public eye back into the quieter, shaded groves of
academe. Attendance at the annual AAAI conference, which
had shot up from fewer than 1,000 at the beginning of the
decade to more than 5,000 in the mid-1980s, slumped to
about 2,000 by the early 1990s, even as the sprawling vendor
displays gradually disappeared; it has since settled back to a
respectable steady state of about 1,000 core academics
reporting steady if relatively unheralded progress [19,20].
Just as AAAI attendance ﬁgures and corporate R&D
budgets declined, the genome project was ramping up and
creating an unprecedented demand for computational
support. A cynic might observe that this was a convenient
time for me to rediscover my roots in molecular biology,
though in fact I had already been working for several years to
set up a Biomedical Knowledge Systems group at Unisys, and
with my late colleague Chris Overton managed to attract
several US National Institutes of Health grants as in-house
resources dried up. Now, as the strictures of an industry
struggling to reinvent itself closed in, a gap seemed to open
between the science and the business, between the pure and
the applied, that had never troubled me before. I couldn’t
disagree with business decisions geared to survival and made
many of them myself, but what had before seemed an easy
alliance of creative push with strategic pull was now coming
apart. Meanwhile, the immense scientiﬁc promise of large-
scale genome sequencing and its attendant computational
challenges beckoned.
Once More unto the Bench
So it was that in 1991, an offer from the University of
Pennsylvania (Penn) to join their faculty and to help build a
genome center and informatics lab proved irresistible. Chris
and I moved as a team and eagerly set up shop. Almost
immediately, the peculiar institution of academia threw up
challenges I had nearly forgotten; for instance, there was the
matter of academic appointments, which proved problematic
for hide-bound committees that couldn’t readily countenance
a hybrid enterprise like bioinformatics [21]. Did we really
belong in a biology department or in computer science?
Could much-needed support to bench scientists be
reconciled with original computational research? By which
standards and conventions should our career development be
judged? (Accommodating the hybrid nature of informatics
was especially important to me with my research interest at
the time in macromolecular linguistics, which spanned the
range from formal language theory [22] to practical DNA
parsing applications [23].) And, of course, it was back to the
treadmill of churning out grant applications. Paylines were
then at one of their periodic low ebbs—though liberal in
comparison with the current situation—and while I managed
to keep several balls in the air successfully, raising money
soon occupied vast swathes of my time.
Still, it was a remarkable era for bioinformatics. Crucially,
the new discipline was proving its versatility, as the demands
of the genome project required a diversiﬁcation from its early
algorithmic focus on efﬁcient string comparison and pattern
matching to the combinatorial concerns of genetic and
physical mapping, sequence assembly, and so forth. (These
are phases of the development of bioinformatics to which I
like to refer as Linear A and Linear B, respectively.) In major
projects, bioinformatics gradually moved from an ancillary
role to a central one, and institutions followed, albeit with a
time lag. At the same time, the infrastructure of a true
scientiﬁc discipline began to coalesce: new and more
respectable journals, textbooks, programs of study, and so
forth. Larry Hunter, Jude Shavlik, and I drew on the AI
tradition of bioinformatics in organizing the ﬁrst ISMB
(Intelligent Systems for Molecular Biology) meeting in 1993,
which attracted a little over a hundred people [24]. It grew
year by year to become the premier conference in the ﬁeld
(with RECOMB [Research in Computational Molecular
Biology], which pulled in the mathematical and algorithmic
family branches), now drawing up to 2,000 attendees and
attendant ﬂashy vendor displays. The early ISMB and
RECOMB meetings also gave rise to the ISCB (International
Society for Computational Biology), so that with vigorous
conference series and a scientiﬁc society, the ﬁeld had
suddenly grown up [25]. Truly, it seemed like a Bioinformatics
Spring.
‘‘That’s No Moon . . .’’
It was on this upswing that a new opportunity presented
itself to me, at SmithKline Beecham (SB). The company had
spent $125,000,000 (a lot of money at the time) on a deal to
obtain a data stream of ESTs and now wanted to augment the
small group managing that data to develop a science-driven
bioinformatics function to leverage the investment [11]. I was
offered ‘‘unlimited’’ headcount to build a unit (with the
obligatory tag ‘‘world class’’) that would move SB into the
forefront of bioinformatics.
The decision to move to industry in 1995 was more difﬁcult
than it had been a decade earlier. Academia was rapidly
warming to the ﬁeld, and was ﬁnding ways to accommodate it
with formal interdisciplinary programs, cross-departmental
institutes, and even dedicated departments. But again, this
loomed as a long, incremental process—what clinched it for
me was the opportunity to do things on scale, to design and
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a dime, all at once rather than a grant at a time.
SB was as good as its word, and indeed the primary
impediment to growth was the difﬁculty of ﬁnding qualiﬁed
staff in those early days [1]. Year by year my group doubled
and doubled again. While there was criticism of SB and other
companies for sponging up so many informatics workers, in
fact this was a minor effect compared with the rate of
maturation of the ﬁeld as a whole. The draw from industry
did far more good than harm in validating the importance of
the discipline and establishing the economic demand, to
which academia rapidly responded with a supply of both
science and trainees. Chris Overton used to say with a wry
smile that my leaving was the best thing that ever happened
to bioinformatics at Penn (a statement I chose to interpret in
a positive light).
Plus c ¸a Change ...
Today, industry demand has long since reached a steady
state; what is remarkable is that it has not appreciably
declined. No longer does informatics have the star power to
draw feverish investment by pharma, but rather it has become
part of the backdrop of discovery—an essential part, to be
sure, but not a supernova in itself. There have been many
cases of pharma technologies, such as combinatorial
chemistry or rational design, that ﬂared brieﬂy (perhaps fed
by a bit too much hype) and then subsided back into a
contributing role—never quite revolutionizing drug
discovery from the ground up, but certainly becoming part of
the constellation of tools. Informatics was fortunate, I think,
to hit a peak just as it hit its stride in industry, one that was
sustainable by virtue of its becoming foundational. By
contrast, the burst of bioinformatics startups in the 1990s
largely came and went, generally failing to gain traction, at
least as a ‘‘pure play.’’
A key reason for this staying power in industry has been
that attribute of versatility. After the ‘‘linear’’ phases of
bioinformatics, supporting ESTs and genome sequencing, the
‘‘omic’’ phase drove development of methods to deal with
high-dimensional data. Not being tied to any particular
technology platform, informatics groups were able to adapt
with aplomb. Now the systems phase is driving new modeling
methods and network views, and again informatics is making
itself not only useful but crucial, particularly with its
integrative powers as data sources explode in both volume
and diversity. Industry informatics groups have continuously
reinvented themselves and largely thrived—provided that
they are not pigeonholed into strict functional roles but are
allowed to adapt, just as their academic cognates are well-
suited to do over time. Ironically, it may have been the
standalone informatics vendors who were most disadvantaged
by the shifting data and technology landscape, in that they
had to commit to extended product lifecycles that simply
could not keep pace, even with the public domain.
De ´ja ` Vu All over Again
Having felt the chill of the AI Winter and the decline of
mainframes, I developed an exquisitely sensitive built-in de ´ja `
vu meter, which pinned in 2000 when SB and GlaxoWellcome
merged to form GlaxoSmithKline (GSK). Each of the parent
companies had themselves been formed by mega-mergers
within the previous decade, and their combination now
formed the second-largest pharma worldwide. By chance,
each had invested relatively heavily in internal informatics
capabilities, and so this time the groups were more alike than
different and their cultures combined fairly smoothly and to
good effect. Not all mergers are created equal, and this one
has worked well, but there is no denying the fact that they are
a lot of work and that these recurrent paroxysms of industry
are in marked contrast to the organizational stability of
academia. Mergers and major reorganizations are just the
most obvious manifestations of the relatively more rapid
adaptations that characterize the commercial side, for better
or worse.
However, the constant struggle to optimize organization in
industry is periodically mirrored in academia, precisely at the
point at which scientiﬁc disciplines evolve. When I ﬁrst
arrived at Penn there was no comfortable home for the new
interdisciplinary ﬁeld of bioinformatics, but academia
adjusted, ﬁnding new ways to bridge that particular divide
between molecular biology and engineering [26]. That same
divide abides in industry, where IT (information technology)
groups are traditionally functionally distinct from the
scientiﬁc lines. Where to put informatics? In my 12 years in
this particular business, I believe I’ve managed groups in
nearly every possible conﬁguration, starting my pharma
career in the IT line, then moving to the discovery
organization, at one point running a bioinformatics function
separate from cheminformatics, then combined; and with
either a full-service scientiﬁc and engineering remit or, most
recently, with one focused exclusively on the scientiﬁc/
analytical function. Each architecture had its strengths and
weaknesses, depending on the wider context, and to this day I
couldn’t swear one is superior overall. Whatever the org chart
says, what is essential is that the informatics be embedded
with the bench science and that the engineering be
embedded with the informatics, in an intimate association
with minimal ‘‘starting friction’’ and an appreciation on all
sides of the difference between traditional IT and scientiﬁc
computing.
Thus, far more important than the organization of
departments into lines (or schools) is the effective
communication and interaction among them—what is called
working in the matrix—and this is where pharma excels, even
over other industries. Drug discovery by its nature is a series
of temporal and functional handoffs, but these can only be
effective when there is both continuity and, at any given
point, the collective application of multiple interdependent
skill sets. Academia tends to accomplish this through ad hoc
collaborations and exchanges of reagents (what we used to
call ‘‘clone by phone’’), or on a larger scale by establishing
interdisciplinary centers and institutes with cross-
appointments of faculty; pharma does it as a matter of course.
On any given project team, the range of scientiﬁc specialties
arrayed against a problem is fascinating to behold, the more
so because it is taken for granted, as an unremarkable aspect
of doing business. Thus informatics, a quintessentially
interdisciplinary pursuit, assumes a very natural place in the
matrix of pharma. Moreover, its versatility allows it to keep
pace with the rate of technological change embraced in
industry, while organizationally mirroring the continuous
reinvention of the ﬁeld as a whole.
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Pharma is facing many external pressures in the present
age, economic and otherwise, all readily apparent in the news
media; one response to this is an increasing virtualization of
the industry, by which formerly monolithic and largely self-
contained R&D enterprises are increasingly outward-facing.
This trend to virtualization takes many forms, from
offshoring of support activities, to outsourcing of key
processes, to inlicensing of assets, to academic collaborations,
to precompetitive consortia—all with an increasingly global
reach. In truth, pharma has always depended to a signiﬁcant
degree on academia for the most exploratory new science and
on startups for the riskiest new technology, so the change is
more quantitative than qualitative. But for an itinerant like
me, it’s gratifying to see that the economic drivers of this
industry not only call for a wonderfully stimulating
smorgasbord of skills, but for the continuous exchange of
science, technology, and people too. It’s hard to imagine that
dynamic disappearing under any future model of pharma,
whatever the economic pressures and however radical the
changes. Informatics is not a dalliance for pharma, it is
ingrained now in the process. At the same time, pharma by its
integrative nature provides the major economic exigency for
informatics technology.
In short, I no longer worry about an Informatics Winter,
even with chill winds about—there’s light on the Dark Side. &
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